Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 47Squamous Cell Carcinoma of Head and Neck 24Head and Neck Neoplasms 21Lung Neoplasms 19Neoplasms 18Stomach Neoplasms 15Urinary Bladder Neoplasms 14Uterine Cervical Neoplasms 11Small Cell Lung Carcinoma 11Ovarian Neoplasms 11Esophageal Neoplasms 11Colorectal Neoplasms 11Pancreatic Neoplasms 10Biliary Tract Neoplasms 10Carcinoma, Transitional Cell 9Triple Negative Breast Neoplasms 8Neoplasm Metastasis 8Cholangiocarcinoma 8Breast Neoplasms 8Oropharyngeal Neoplasms 7Mesothelioma, Malignant 7Melanoma 7Carcinoma, Squamous Cell 6Recurrence 5Nasopharyngeal Carcinoma 5Mesothelioma 5Esophageal Squamous Cell Carcinoma 5Carcinoma 5Nasopharyngeal Neoplasms 4Mouth Neoplasms 4

Interventions

regorafenib 1Paclitaxel 1Everolimus 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Unresectable Locally Advanced or Metastatic Solid Tumors × Cisplatin × Clear all
NCT06682611 2024-11-12

Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.

Shanghai Runshi Pharmaceutical Technology Co., Ltd

Phase 1/2 Not yet recruiting
380 enrolled
Other solid neoplasm

Unresectable Locally Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡